Drug Type Monoclonal antibody |
Synonyms ABP300 Abpro Therapeutics/Mabwell Biosciences, ABP300 COVID2019 infections |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 28 Nov 2020 |